Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Medpace, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study sites. This is an extension study of protocol OB-303 (NCT00553787).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Placebo |
|
| VI-0521 Mid | Experimental | 7.5 mg phentermine and 46 mg topiramate |
|
| VI-0521 Top | Experimental | 15 mg phentermine and 92 mg topiramate |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| VI-0521 | Drug | 7.5 mg phentermine and 46 mg topiramate |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Percent Weight Change at End of Treatment, Week 108. | From baseline to end of treatment | |
| Percentage of Subjects With at Least 5% Weight Loss at End of Treatment, Week 108. | Baseline to End of Treatment |
Not provided
Not provided
Inclusion Criteria:
To be eligible for enrollment into this study, subjects must meet all of the following criteria:
Exclusion Criteria:
Subjects will not be included in the study if they meet any of the following:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Craig Peterson | VIVUS LLC | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28455281 | Derived | Guo F, Garvey WT. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release. Diabetes Care. 2017 Jul;40(7):856-862. doi: 10.2337/dc17-0088. Epub 2017 Apr 28. | |
| 22158731 | Derived |
| Label | URL |
|---|---|
| VIVUS company website | View source |
Not provided
Not provided
Subjects were from OB-303 (NCT00553787)
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo | Placebo |
| FG001 | VI-0521 Mid | VI-0521 7.5 mg PHEN/46 mg TPM |
| FG002 |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | placebo |
|
| VI-0521 | Drug | 15 mg phentermine and 92 mg topiramate |
|
|
| Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 Feb;95(2):297-308. doi: 10.3945/ajcn.111.024927. Epub 2011 Dec 7. |
| VI-0521 Top |
VI-0521 15 mg PHEN/92 mg TPM |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo | Placebo |
| BG001 | VI-0521 Mid | VI-0521 7.5 mg PHEN/46 mg TPM |
| BG002 | VI-0521 Top | VI-0521 15 mg PHEN/92 mg TPM |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percent Weight Change at End of Treatment, Week 108. | Intent-to-Treat Last observation carried forward (ITT-LOCF) | Posted | Least Squares Mean | Standard Error | percent weight loss | From baseline to end of treatment |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Subjects With at Least 5% Weight Loss at End of Treatment, Week 108. | Intent-to-treat Last-observation-carried-forward (ITT-LOCF) | Posted | Number | percent participants | Baseline to End of Treatment |
|
|
AEs were collected from when written informed consent was provided through 28 days after the last dose of investigational product.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | Placebo | 9 | 227 | 182 | 227 | ||
| EG001 | VI-0521 Mid | VI-0521 7.5 mg PHEN/46 mg TPM | 4 | 153 | 111 | 153 | ||
| EG002 | VI-0521 Top | VI-0521 15 mg PHEN/92 mg TPM | 13 | 295 | 234 | 295 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ankle fracture | Injury, poisoning and procedural complications | MedDRA (10.1) | Systematic Assessment |
| |
| humerus fracture | Injury, poisoning and procedural complications | MedDRA (10.1) | Systematic Assessment |
| |
| hemorrhage intracranial | Nervous system disorders | MedDRA (10.1) | Systematic Assessment |
| |
| transient ischemic attack | Nervous system disorders | MedDRA (10.1) | Systematic Assessment |
| |
| cerebrovascular accident | Nervous system disorders | MedDRA (10.1) | Systematic Assessment |
| |
| ischemic stroke | Nervous system disorders | MedDRA (10.1) | Systematic Assessment |
| |
| depression | Psychiatric disorders | MedDRA (10.1) | Systematic Assessment |
| |
| peptic ulcer hemorrhage | Gastrointestinal disorders | MedDRA (10.1) | Systematic Assessment |
| |
| inguinal hernia, obstructive | Gastrointestinal disorders | MedDRA (10.1) | Systematic Assessment |
| |
| abdominal hernia | Gastrointestinal disorders | MedDRA (10.1) | Systematic Assessment |
| |
| nephritic syndrome | Renal and urinary disorders | MedDRA (10.1) | Systematic Assessment |
| |
| renal failure, acute | Renal and urinary disorders | MedDRA (10.1) | Systematic Assessment |
| |
| pneumonia | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| appendicitis | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| pyelonephritis | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| influenza | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| mesothelioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (10.1) | Systematic Assessment |
| |
| hypotension | Vascular disorders | MedDRA (10.1) | Systematic Assessment |
| |
| drug hypersensitivity | Immune system disorders | MedDRA (10.1) | Systematic Assessment |
| |
| arthralgia | Musculoskeletal and connective tissue disorders | MedDRA (10.1) | Systematic Assessment |
| |
| osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA (10.1) | Systematic Assessment |
| |
| serositis | General disorders | MedDRA (10.1) | Systematic Assessment |
| |
| myocardial infarction | Cardiac disorders | MedDRA (10.1) | Systematic Assessment |
| |
| acute myocardial infarction | Cardiac disorders | MedDRA (10.1) | Systematic Assessment |
| |
| cholecystitis | Hepatobiliary disorders | MedDRA (10.1) | Systematic Assessment |
| |
| acute cholecystitis | Hepatobiliary disorders | MedDRA (10.1) | Systematic Assessment |
| |
| cholelithiasis | Hepatobiliary disorders | MedDRA (10.1) | Systematic Assessment |
| |
| uterine prolapse | Reproductive system and breast disorders | MedDRA (10.1) | Systematic Assessment |
| |
| benign prostatic hyperplasia | Reproductive system and breast disorders | MedDRA (10.1) | Systematic Assessment |
| |
| cervical dysplasia | Reproductive system and breast disorders | MedDRA (10.1) | Systematic Assessment |
| |
| respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA (10.1) | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| upper respiratory tract infection | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| nasopharyngitis | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| sinusitis | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| urinary tract infection | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| influenza | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| bronchitis | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| constipation | Gastrointestinal disorders | MedDRA (10.1) | Systematic Assessment |
| |
| nausea | Gastrointestinal disorders | MedDRA (10.1) | Systematic Assessment |
| |
| arthralgia | Musculoskeletal and connective tissue disorders | MedDRA (10.1) | Systematic Assessment |
| |
| back pain | Musculoskeletal and connective tissue disorders | MedDRA (10.1) | Systematic Assessment |
| |
| insomnia | Psychiatric disorders | MedDRA (10.1) | Systematic Assessment |
| |
| procedural pain | Injury, poisoning and procedural complications | MedDRA (10.1) | Systematic Assessment |
| |
| musculoskeletal pain | Musculoskeletal and connective tissue disorders | MedDRA (10.1) | Systematic Assessment |
| |
| pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA (10.1) | Systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| gastroenteritis viral | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| ear infection | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| tooth abscess | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| pneumonia | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| viral infection | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| tooth infection | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| oral herpes | Infections and infestations | MedDRA (10.1) | Systematic Assessment |
| |
| osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA (10.1) | Systematic Assessment |
| |
| muscle spasms | Musculoskeletal and connective tissue disorders | MedDRA (10.1) | Systematic Assessment |
| |
| myalgia | Musculoskeletal and connective tissue disorders | MedDRA (10.1) | Systematic Assessment |
| |
| diarrhea | Gastrointestinal disorders | MedDRA (10.1) | Systematic Assessment |
| |
| tooth ache | Gastrointestinal disorders | MedDRA (10.1) | Systematic Assessment |
| |
| abdominal pain | Gastrointestinal disorders | MedDRA (10.1) | Systematic Assessment |
| |
| hemorrhoids | Gastrointestinal disorders | MedDRA (10.1) | Systematic Assessment |
| |
| vomiting | Gastrointestinal disorders | MedDRA (10.1) | Systematic Assessment |
| |
| abdominal discomfort | Gastrointestinal disorders | MedDRA (10.1) | Systematic Assessment |
| |
| joint sprain | Injury, poisoning and procedural complications | MedDRA (10.1) | Systematic Assessment |
| |
| muscle strain | Injury, poisoning and procedural complications | MedDRA (10.1) | Systematic Assessment |
| |
| contusion | Injury, poisoning and procedural complications | MedDRA (10.1) | Systematic Assessment |
| |
| cough | Respiratory, thoracic and mediastinal disorders | MedDRA (10.1) | Systematic Assessment |
| |
| pharyngolaryngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA (10.1) | Systematic Assessment |
| |
| sinus congestion | Respiratory, thoracic and mediastinal disorders | MedDRA (10.1) | Systematic Assessment |
| |
| headache | Nervous system disorders | MedDRA (10.1) | Systematic Assessment |
| |
| paresthesia | Nervous system disorders | MedDRA (10.1) | Systematic Assessment |
| |
| depression | Psychiatric disorders | MedDRA (10.1) | Systematic Assessment |
| |
| anxiety | Psychiatric disorders | MedDRA (10.1) | Systematic Assessment |
| |
| diabetes mellitus | Metabolism and nutrition disorders | MedDRA (10.1) | Systematic Assessment |
| |
| dyslipidemia | Metabolism and nutrition disorders | MedDRA (10.1) | Systematic Assessment |
| |
| weight increased | Investigations | MedDRA (10.1) | Systematic Assessment |
| |
| hemoglobin decreased | Investigations | MedDRA (10.1) | Systematic Assessment |
| |
| abdominal bruit | Investigations | MedDRA (10.1) | Systematic Assessment |
| |
| edema peripheral | General disorders | MedDRA (10.1) | Systematic Assessment |
| |
| eye pain | Eye disorders | MedDRA (10.1) | Systematic Assessment |
| |
| hypertension | Vascular disorders | MedDRA (10.1) | Systematic Assessment |
| |
| seasonal allergy | Immune system disorders | MedDRA (10.1) | Systematic Assessment |
|
After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution & PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Wesley W Day, PhD | Vivus, Inc | 650.934.5200 | day@vivus.com |
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C576188 | Qsymia |
| C577572 | Qnexa |
Not provided
Not provided
Not provided
| Male |
|
No formal calculation of sample size was conducted due to being an extension study of OB-303 (NCT00553787) |
| ANCOVA |
| <0.0001 |
Intersection-union method applied in a step-down testing approach |
| Mean Difference (Final Values) |
| 7.52 |
| Standard Error of the Mean |
| 0.799 |
| 2-Sided |
| 95 |
| 5.95 |
| 9.09 |
| No |
| Superiority or Other |
| No formal calculation of sample size was conducted due to being an extension study of OB-303 (NCT00553787) | ANCOVA | 0.1189 | Intersection-union method applied in a step-down testing approach | Mean Difference (Final Values) | 1.19 | Standard Error of the Mean | 0.760 | 2-Sided | 95 | -0.31 | 2.68 | No | Superiority or Other |
|
|